HTX-001
Phase 1/2- Indications
- Infant health
Company intelligence / Profile preview
Persephone Biosciences has advanced multiple programs into the clinic. Its infant synbiotic product entered the ARTEMIS clinical trial in early 2025 to assess effects on babies' and toddlers' microbiomes. The company’s ARGONAUT study remains one of the largest U.S. efforts mapping the gut–immune axis to identify cancer biomarkers. Early results have enabled collaborations with major pharma partners but no pivotal/late-stage data disclosed yet.[7][10]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Persephone Biosciences.